Drug Pricing Debate Will Carry Over To 2020
Executive Summary
An eventful year for sweeping drug pricing legislative proposals in the US will end with enactment of a long-standing carryover proposal – new procedures intended to address perceived abuses of the REMS process – but nothing more substantial for the drug industry.
You may also be interested in...
MedPAC To The Rescue? How US Policy Advisors Could Save The Drug Industry
The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.
Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
Bill To Lower Pay Of Out-Of-Network Physicians, Costs Delayed To 2020
A bill meant to stop out-of-network "surprise billing" may have stalled but is likely to make a reappearance when Congress reconvenes next year according to lawmakers and experts. Despite support in key Senate and House committees, the bill hit a wall when lawmakers introduced an alternative version in the House Ways and Means Committee late in the legislative session.